Anthony James Culverwell Purchases 6,146 Shares of Quoin Pharmaceuticals (NASDAQ:QNRX) Stock

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Director Anthony James Culverwell purchased 6,146 shares of the stock in a transaction on Monday, August 31st. The shares were acquired at an average cost of $4.88 per share, for a total transaction of $29,992.48. Following the transaction, the director owned 40,364 shares of the company’s stock, valued at approximately $196,976.32. The trade was a 17.96% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Quoin Pharmaceuticals Trading Up 4.7%

NASDAQ:QNRX traded up $0.29 on Tuesday, hitting $6.51. The company’s stock had a trading volume of 274,471 shares, compared to its average volume of 1,602,162. Quoin Pharmaceuticals, Ltd. Sponsored ADR has a one year low of $3.25 and a one year high of $41.80. The firm has a market capitalization of $13.09 million, a P/E ratio of -0.26 and a beta of 1.50. The stock has a fifty day moving average of $4.77 and a two-hundred day moving average of $5.89.

Quoin Pharmaceuticals (NASDAQ:QNRX) last issued its earnings results on Friday, August 14th. The company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.61) by ($0.29). As a group, sell-side analysts anticipate that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -7.38 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on QNRX. ThinkEquity assumed coverage on shares of Quoin Pharmaceuticals in a research report on Monday, June 15th. They set a “buy” rating for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a report on Monday, July 20th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold”.

Institutional Investors Weigh In On Quoin Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Simplify Asset Management Inc. bought a new stake in shares of Quoin Pharmaceuticals during the fourth quarter worth approximately $252,000. SummitTX Capital L.P. increased its stake in shares of Quoin Pharmaceuticals by 54.8% during the first quarter. SummitTX Capital L.P. now owns 100,300 shares of the company’s stock worth $662,000 after purchasing an additional 35,505 shares during the period. ADAR1 Capital Management LLC acquired a new stake in Quoin Pharmaceuticals during the 4th quarter worth approximately $840,000. Boothbay Fund Management LLC acquired a new stake in Quoin Pharmaceuticals during the 4th quarter worth approximately $863,000. Finally, Millennium Management LLC bought a new stake in Quoin Pharmaceuticals in the 4th quarter valued at $1,080,000. 8.63% of the stock is currently owned by institutional investors and hedge funds.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.